Baird raised the firm’s price target on Procept BioRobotics (PRCT) to $28 from $27 and keeps a Neutral rating on the shares. The firm updated its model following Q1 beat results but long term adoption trajectory keeps them on the sidelines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- PROCEPT BioRobotics: Buy Rating Reaffirmed on Strong Q1 Performance and Multi‑Year Outlook, Price Target Unchanged at $34
- Closing Bell Movers: Meta falls 6%, Alphabet jumps 6% after earnings
- Procept BioRobotics affirms FY26 revenue $390M-$410M, consensus $395.9M
- Procept BioRobotics reports Q1 EPS (56c), consensus (55c)
- PROCEPT BioRobotics: Depressed Valuation, Transitory Destocking, and Underappreciated Multi‑Year Growth Runway Support Buy Rating